PHAT

Phathom Pharmaceuticals, Inc. [PHAT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHAT Stock Summary

Top 10 Correlated ETFs

PHAT

Top 10 Correlated Stocks

PHAT

In the News

PHAT Financial details

Company Rating
-
Market Cap
592.96M
Income
-201.45M
Revenue
682K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
452
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.55
Forward P/E
-
PEG
0.8
P/S
-
P/B
-26.61
P/C
-
P/FCF
-3.51
Quick Ratio
8.91
Current Ratio
9.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.88
EPS next Y
-
EPS next Q
-
EPS this Y
-31.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
82.89%
-
-
-
-
SMA20
20%
SMA50
-14.29%
SMA100
-66.67%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
449%
ROC
-0.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.065-17.019
52W High
-70.44%
52W Low
-16.25%
RSI
44
Rel Volume
1.13
Avg Volume
917.88K
Volume
1.04M
Perf Week
-21.73%
Perf Month
-11.38%
Perf Quarter
-68.01%
Perf Half Y
-72.21%
-
-
-
-
Beta
0.627
-
-
Volatility
0.64%, 0.68%
Prev Close
-8.47%
Price
5.025
Change
0.9%

Something similar

Top by Market Cap
TSLA
AAPL
BRK-B
GOOGL
FB2A.DE
Top Correlated ETFs
QDV5.DE
IIND.L
INQQ
EVNT
XTAP
Top Correlated Stocks
BRE.TO
BNCC
WOW
MED.SW
AII.TO
Similar Market Cap
CPAAU
PFG.L
BTIEX
AGQ
AMS.SW

Company Profile

Healthcare Biotechnology
  • Volume Average 917.88K
  • Market Capitalization 592.96M
  • Employee 452
  • CEO Ms. Terrie J. Curran
  • Headquarters Florham Park,NJ,US
  • IPO Date 2019-10-25
  • Website https://www.phathompharma.com

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.